Events

Events

View Here
View Here
Save the date! CEO Helen Ljundahl Round and CFO Christian Lindholm present the company’s Q1 2023 report.
Link to Event
Save the Date! Redeye hosts its eighth Medtech event. Redeye has invited several interesting Medtech companies from different areas and development stages, including Acarix. Each company will present their businesses, view on the market opportunities and challenges ahead. The event will begin with an introduction to the Medtech sector by one of the Redeye analysts. Tune in for an exciting event that hopefully will generate new investment ideas in a sector that might rebound as a winner coming years. Following the presentations, Redeye’s analysts will hold Q&A sessions where questions are open to the audience.
Link to event
Redeye Investor Forum is a live broadcast where different companies, including Acarix, will show a 12-minute presentation followed by an 8-minute Q&A moderated by Redey analysts. You can ask your question directly to the companies during the live broadcast in the question form.
Join the presentation
Acarix will present at the 2023 Aktiespararna Share Day in Stockholm on May 3, 2023 Nine CEOs, including Acarix CEO Helen Ljungdahl Round, will present their company. In addition, there will be stock market and equity analysis with Aktiespararna’s Robert Anderson and Ola Jansson.
Register
View  the Presentation
View the Presentation

American College of Cardiology & World Congress of Cardiology

March 4-6 2023 New Orleans

Booth #449

View the Presentation
Join us on November 24th at 14.50 CET to hear Helen Ljungdahl Round, CEO of Acarix present at Redeye Life Science Day 2022. The presentation will showcase the company’s latest developments and include an in-depth interview with Q&A. market and equity analysis with Aktiespararna’s Robert Anderson and Ola Jansson.
Watch video
Watch webcast here
Watch Presentation here
Join the event here

An acoustic based risk score in addition to pre-test probability estimation for coronary artery disease improves risk classification in patients with suspected coronary artery disease. Louise Bjerking (Bispebjerg University Hospital – Copenhagen, Denmark).

Best of the European Heart Journal – Digital Health Advanced heart sound analysis as a new prognostic marker in stable coronary artery disease. Simon Winther (Goedstrup Hospital – Herning, Denmark)

Join the event here

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based Coronary Artery Disease (CAD) rule-out.

The CE-mark approved and FDA De Novo cleared Acarix CADScor®System is for patients experiencing stable chest pain with suspected CAD and is designed to help reduce millions of unnecessary and costly diagnostic procedures.2 CADScor®System calculates a patient-specific CAD-score non-invasively in 10 minutes with at least 96% confidence (Negative Predictive Value).¹

Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).

Learn more

Contact Us

Please visit our contact page to get in touch.

go to contact page
  1. User manual US-FDA v.12.Y, prevalence 10,7%
  2. Shaw LJ, Marwick TH, Zoghbi WA, Hundley WG, Kramer CM, Achenbach S, Dilsizian V, Kern MJ, Chandrashekhar Y, Narula J. Why all the focus on cardiac imaging? JACC Cardiovasc Imaging. 2010 Jul;3(7):789-94. doi: 10.1016/j.jcmg.2010.05.004. PMID: 20633864.